Rapidly progressive interstitial pneumonia associated with anti-NXP2 antibody secondary to malignancy. (2022)

• Record Type: Journal Article
• Authors: Wuthithepbuncha, Nataphon; Boonsarngsuk, Viboon; Laikitmongkhon, Jakkrit; Incharoen, Pimpin; Sukkasem, Warawut
• Is Part Of: Respiratory medicine case reports. Volume 40(2022)
• Publication Date: 2022
• Subjects: Interstitial pneumonia -- Connective tissue disease-related interstitial lung disease -- Acute interstitial pneumonitis -- Myositis specific antibodies; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2022.101765
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: The diagnosis of a diffuse lung disease is challenging for physicians and it requires a multidisciplinary team approach to solve this problem. Herein, we present a case of common bile duct obstruction from pancreatic ductal adenocarcinoma after biliary stent placement, which developed a rapidly progressive bilateral lung infiltration after oesophagogastroduodenoscopy. After a diagnostic evaluation based on clinical, radiographic, and pathological findings, a diagnosis of rapidly progressive interstitial pneumonia associated with anti-nuclear matrix protein (NXP) 2 antibody secondary to malignancy was made. In patients with interstitial lung disease with unclear aetiologies, autoantibodies, including antinuclear antibody and myositis-specific antibodies should be evaluated, even if there are no clinical signs of autoimmune disease. Although this is the first case report of an acute interstitial pneumonitis-associated anti-NXP2 antibody, physicians should recognise this condition as it can rapidly cause acute fulminant respiratory failure.